Innate Immune Cells and C-Reactive Protein in Acute First-Episode Psychosis and Schizophrenia: Relationship to Psychopathology and Treatment
Overview
Authors
Affiliations
Innate immunity has been linked to initiation of Alzheimer's disease and multiple sclerosis. Moreover, risk of first-episode psychosis (FEP) and schizophrenia (Sz) is increased after various infections in predisposed individuals. Thus, we hypothesized an analogous role of innate immunity with increased C-reactive protein (CRP) in non-affective psychosis. Differential blood count, CRP, neutrophil and monocyte-macrophage activation markers, cortisol and psychotic symptoms (Positive and Negative Syndrome Scale [PANSS]) were assessed in controls (n = 294) and acutely ill unmedicated FEP (n = 129) and Sz (n = 124) patients at baseline and after 6 weeks treatment. Neutrophils, monocytes, and CRP were increased in patients vs controls at baseline (P < .001), and neutrophil and monocyte counts correlated positively with activation markers. Eosinophils were lower at baseline in FEP (P < .001) and Sz (P = .021) vs controls. Differences in neutrophils (P = .023), eosinophils (P < .001), and CRP (P < .001) were also present when controlling for smoking and cortisol, and partially remitted after antipsychotic treatment. FEP patients with high neutrophils (P = .048) or monocytes (P = .021) had higher PANSS-P scores at baseline but similar disease course. CRP correlated with PANSS-P at baseline (ρ = 0.204, P = .012). Improvement of positive symptoms after treatment correlated with declining neutrophils (ρ = 0.186, P = .015) or CRP (ρ = 0.237, P = .002) and rising eosinophils (ρ = -0.161, P = .036). In FEP, normalization of neutrophils (ρ = -0.231, P = .029) and eosinophils (ρ = 0.209, P = .048) correlated with drug dosage. In conclusion, innate immune system activation correlated with PANSS-P, supporting the immune hypothesis of psychosis. Neutrophil and monocyte counts and CRP levels may be useful markers of disease acuity, severity, and treatment response.
Dudeck L, Nussbaumer M, Nickl-Jockschat T, Guest P, Dobrowolny H, Meyer-Lotz G JAMA Psychiatry. 2025; .
PMID: 40042836 PMC: 11883609. DOI: 10.1001/jamapsychiatry.2024.4941.
Liu J, Zhao W, Wang Y Metab Brain Dis. 2025; 40(2):128.
PMID: 39954151 DOI: 10.1007/s11011-025-01558-1.
Tao S, Wu Y, Xiao L, Huang Y, Wang H, Tang Y Transl Psychiatry. 2025; 15(1):35.
PMID: 39880843 PMC: 11779829. DOI: 10.1038/s41398-025-03239-0.
Rong G, Li X, Lu H, Su M, Jin Y Front Nutr. 2024; 11:1415132.
PMID: 39734669 PMC: 11671254. DOI: 10.3389/fnut.2024.1415132.
Lotfi N, Rezaei N, Rastgoo E, Khodadoustan Shahraki B, Zahedi G, Jafarinia M Galen Med J. 2024; 12:e3109.
PMID: 39553412 PMC: 11568428. DOI: 10.31661/gmj.v12i.3109.